关键词: font-size:medium, ">口服降糖药；销售金额；用药频度；限定日费用；排序比

Abstract: Objective： Statistics and analysis have been made on the use of oral hypoglycemic drugs at the inpatient of a hospital from 2020 to 2022，so as to provide reference for the rational use of oral hypoglycemic drugs. Methods： The application data of inpatients with oral hypoglycemic drugs in a hospital from 2020 to 2022 were collected to obtain the annual total amount of sales and the annual total amount of delivery， etc. The defined daily dose (DDD) analysis method recommended by the World Health Organization was adopted. The consumption sum， defined daily dose system(DDDs)， defined daily cost(DDC) and sequence number ratio(B/A) of oral hypoglycemic drugs in a hospital were analyzed retrospectively. Results： From 2020 to 2022， the total consumption sum of various oral hypoglycemic drugs in a hospital increased annually， and the consumption sum of dipeptidyl peptidase (DPP-4) inhibitors ranked first for three consecutive years. The DDDs of metformin and dagliazine occupied the first two in the second two years； Pioglitazone DDC ranked first for 3 consecutive years， and metformin DDC decreased most obviously. The maximum B/A was found in metformin and the minimum in Linagliptin. Conclusion： The clinical selection of oral hypoglycemic drugs in a hospital from 2020 to 2022 is basically reasonable and in line with the recommendations of the guidelines.

Key words: Oral hypoglycemic agents, Sales amount, Defined daily dose system, Defined daily cost, B/A